Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsed/Refractory B-Cell Malignancies Males or females, of any race, aged ≥ 18 years Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 Sufficient bone marrow function, hepatic function and Coagulation function Patients must have measurable disease per disease-specific response criteria Have histologically confirmed R/R CLL,SLL,MCL,Non-GCB DLBCL,FL(grade 1 ),MZL,WM Received at least 1 prior systemic therapy(MCL no more than 5 lines of treatment) and have no other therapies known to provide clinical benefit After the most recent treatment regimen, it is confirmed that PR has not been achieved, or there is confirmed progressive disease Must require systemic therapy The pregnancy test (urine or serum) of female subjects of childbearing potential shall be negative before enrollment  Subjects with central nervous system involvement Subjects with histopathological transformation Receipt of allogeneic hematopoietic stem cell transplantation ≤ 180 days before the start of study treatment administration on Cycle 1, Day 1, unless the subject is no longer on immunosuppressant medication. History of autologous hematopoietic stem cell transplantation within 12 weeks (84 days) before the start of study treatment Continuous immunosuppressive therapy, including systemic (such as intravenous or oral) treatment with corticosteroids for the underlying diseases within 2 weeks before the first dose Received any chemotherapy, biological therapy (such as monoclonal antibodies), immunotherapy, Chinese herbal medicines with anti-tumor efficacy, or other anti-tumor treatments within 4 weeks before the first use of HSK29116. The time interval from the last dose of BTK inhibitor or experimental small molecule drug to the first dose of the IMP is 5 times shorter than the half-life of the previously used drug Previously developed toxicity due to anticancer treatment that did not resolve to Grade ≤ 1 (as per NCI-CTCAE 5.0), except for AEs not constituting a safety risk as assessed by the investigator A history of other malignant tumors within 2 years before enrollment, except for basal cell carcinoma or skin squamous cell carcinoma having been adequately treated, or without disease for ≥ 2 years or with other types of cancer with the survival time of greater than 2 years. Subjects with breast or prostate cancer who are on maintenance hormonal therapies following therapeutic procedures with curative intent are permitted Uncontrolled systemic active infections, or other infections or still on intravenous anti-infection treatment Underwent major surgery in the past 4 weeks Known infection with human immunodeficiency virus, or serologic status reflecting active hepatitis B or C infection